Get started
Author

Danijela Lindahl

Institution: BioInvent (Sweden)
Observed institution: BioInvent (Sweden)
ORCID: 0009-0004-4557-3483
Observed ORCID: 0009-0004-4557-3483
OpenAlex ID: A5119942444
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al. · Clinical Cancer Research · 3
PDF
581 Preliminary phase 1 results of clinical trial investigating BI-1910, a tumor necrosis factor receptor 2 (TNFR2) agonist, in solid tumor cancer patients
2025 · Tatiana Hernandez, Bernard Doger, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors
2026 · Ingrid Teige, Kristoffer S. Rohrberg, et al. · Clinical Cancer Research
BI-1808 + pembrolizumab: Responses to a chemotherapy-free regimen in advanced ovarian cancer.
2026 · Anja Williams, Rebecca Kristeleit, et al. · Journal of Clinical Oncology
Supplementary Material S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Table S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
Supplementary Figure S6 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S9 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S3 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S8 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S7 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S5 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Figure S4 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
PDF
Supplementary Table S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
Data from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al.
Promising efficacy of BI-1206, an antibody targeting FcγRIIB in combination with rituximab and acalabrutinib in R/R NHL patients NHL
2025 · Laura Fogliatto, Ana Cordeiro, et al. · Blood
PDF
Works count: 18
Citation count: 4
H-index: 1
I10-index:
Year
Topic
Type